1. Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion.
- Author
-
Zang R, Case JB, Yutuc E, Ma X, Shen S, Gomez Castro MF, Liu Z, Zeng Q, Zhao H, Son J, Rothlauf PW, Kreutzberger AJB, Hou G, Zhang H, Bose S, Wang X, Vahey MD, Mani K, Griffiths WJ, Kirchhausen T, Fremont DH, Guo H, Diwan A, Wang Y, Diamond MS, Whelan SPJ, and Ding S
- Subjects
- Antiviral Agents pharmacology, COVID-19 metabolism, COVID-19 pathology, COVID-19 virology, Endosomes metabolism, Humans, Interferons metabolism, Membrane Fusion drug effects, Severe acute respiratory syndrome-related coronavirus drug effects, Severe acute respiratory syndrome-related coronavirus metabolism, Severe acute respiratory syndrome-related coronavirus pathogenicity, SARS-CoV-2 drug effects, SARS-CoV-2 metabolism, SARS-CoV-2 pathogenicity, Spike Glycoprotein, Coronavirus genetics, Virus Internalization drug effects, Virus Replication drug effects, Endosomes genetics, Hydroxycholesterols pharmacology, Spike Glycoprotein, Coronavirus antagonists & inhibitors, COVID-19 Drug Treatment
- Abstract
Cholesterol 25-hydroxylase ( CH25H ) is an interferon (IFN)-stimulated gene that shows broad antiviral activities against a wide range of enveloped viruses. Here, using an IFN-stimulated gene screen against vesicular stomatitis virus (VSV)-SARS-CoV and VSV-SARS-CoV-2 chimeric viruses, we identified CH25H and its enzymatic product 25-hydroxycholesterol (25HC) as potent inhibitors of SARS-CoV-2 replication. Internalized 25HC accumulates in the late endosomes and potentially restricts SARS-CoV-2 spike protein catalyzed membrane fusion via blockade of cholesterol export. Our results highlight one of the possible antiviral mechanisms of 25HC and provide the molecular basis for its therapeutic development., Competing Interests: Competing interest statement: M.S.D. is a consultant for Inbios, Eli Lilly, Vir Biotechnology, NGM Biopharmaceuticals, and Emergent BioSolutions and on the Scientific Advisory Board of Moderna. The Diamond Laboratory at Washington University School of Medicine in St. Louis has received sponsored research agreements from Moderna. Invention disclosure filed with Washington University in St. Louis for the recombinant VSV-SARS-CoV-2 used herein. W.J.G. and Y.W. are listed as inventors on the patent “Kit and method for quantitative detection of steroids” US9851368B2. W.J.G., E.Y., and Y.W. are shareholders in CholesteniX Ltd., (Copyright © 2020 the Author(s). Published by PNAS.)
- Published
- 2020
- Full Text
- View/download PDF